  
|
|
|
 |
2009 |
|
|
November 17, 2009
|
MethylGene Reports Favorable Phase I Data for MGCD265 in Solid Tumors at the AACR-NCI-EORTC Conference
|
November 5, 2009
|
MethylGene Reports Third Quarter 2009 Financial Results
|
October 21, 2009
|
MethylGene to Present at the 8th Annual BIO Investor Forum
|
October 20, 2009
|
MethylGene Issues Shares to Otsuka Pharmaceutical Co. Ltd.
|
October 14, 2009
|
MethylGene Announces Equity Investment from Otsuka Pharmaceutical Co., Ltd.
|
September 21, 2009
|
MethylGene to Resume Development of its HDAC Inhibitor, MGCD0103 (Mocetinostat)
|
September 15, 2009
|
MethylGene Presents Phase I Data for its Novel Antifungal Agent, MGCD290, at the 49th Annual ICAAC Meeting
|
September 14, 2009
|
MethylGene Presents Preclinical Data for its Beta-Lactamase Inhibitor, MG96077, at the 49th Annual ICAAC Meeting
|
September 9, 2009
|
MethylGene and Otsuka Extend Funded Research Collaboration
|
September 8, 2009
|
MethylGene to Present Data at the 49th Annual ICAAC Meeting
|
September 2, 2009
|
MethylGene Initiates Phase II Program for MGCD265
|
July 31, 2009
|
MethylGene Reports Second Quarter 2009 Financial Results
|
May 29, 2009
|
MethylGene Announces Management Transition
|
May 28, 2009
|
MethylGene Reports Favorable Preliminary Phase I Data for MGCD265 at ASCO
|
May 8, 2009
|
MethylGene Presents Q1 2009 Financial Results
|
April 23, 2009
|
MethylGene Announces Annual Meeting of Shareholders
|
April 21, 2009
|
MethylGene Presents Preclinical Data for MG516 at AACR
|
March 30, 2009
|
MethylGene's Full Year 2008 Financial Results
|
March 27 2009
|
MethylGene Reschedules Full Year 2008 Conference Call to April 7th
|
March 24, 2009
|
Fourth Quarter and Full Year 2008 Results Conference Call Notice
|
|
|
 
|
|
 |
|
